Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
0.9909
-0.0091 (-0.91%)
Nov 18, 2026, 4:00 PM EST - Market closed
Geron Market Cap
Geron has a market cap or net worth of $638.38 million as of November 18, 2026. It is the 12,393rd most valuable company in the world and the 2,499th biggest in the United States. Its market cap has decreased by 11.50% in one year.
Market Cap
638.38M
Enterprise Value
422.13M
1-Year Change
-11.50%
Global Rank
Country Rank
#2,499 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Geron's market cap has increased from $159.40M to $638.38M, an increase of 300.49%. That is a compound annual growth rate of 5.08%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 18, 2026 | 638.38M | -24.24% |
| Dec 31, 2025 | 842.60M | -60.62% |
| Dec 31, 2024 | 2.14B | 86.74% |
| Dec 29, 2023 | 1.15B | 24.20% |
| Dec 30, 2022 | 922.60M | 134.88% |
| Dec 31, 2021 | 392.80M | -20.44% |
| Dec 31, 2020 | 493.70M | 81.71% |
| Dec 31, 2019 | 271.70M | 45.84% |
| Dec 31, 2018 | 186.30M | -35.00% |
| Dec 29, 2017 | 286.60M | -12.99% |
| Dec 30, 2016 | 329.40M | -56.99% |
| Dec 31, 2015 | 765.80M | 49.89% |
| Dec 31, 2014 | 510.90M | -16.42% |
| Dec 31, 2013 | 611.30M | 231.51% |
| Dec 31, 2012 | 184.40M | -5.24% |
| Dec 30, 2011 | 194.60M | -63.43% |
| Dec 31, 2010 | 532.20M | 4.66% |
| Dec 31, 2009 | 508.50M | 37.54% |
| Dec 31, 2008 | 369.70M | -13.62% |
| Dec 31, 2007 | 428.00M | -26.52% |
| Dec 29, 2006 | 582.50M | 4.37% |
| Dec 30, 2005 | 558.10M | 53.45% |
| Dec 31, 2004 | 363.70M | -6.72% |
| Dec 31, 2003 | 389.90M | 337.60% |
| Dec 31, 2002 | 89.10M | -53.52% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Olema Oncology | 644.78M |
| 4D Molecular Therapeutics | 636.52M |
| Design Therapeutics | 635.24M |
| Immix Biopharma | 626.92M |
| Arbutus Biopharma | 619.30M |
| Cullinan Therapeutics | 616.75M |
| Surrozen | 616.07M |
| ArriVent BioPharma | 597.92M |